Kolfarma was born in 2009 from research carried out at the University of Genoa on the potential anti-epileptic effect of a whey protein, Alpha-Lactalbumin (ALAC) .

Results obtained from clinical studies of antidepressant drugs, serotonin reuptake inhibitors (SSRIs) on epileptic patients lead to the search for another way to increase the synthesis of serotonin in the central nervous system (CNS), and not its time of action as reported for these drugs. For this action, ALAC is identified

Kolfarma 's commitment is to promote studies to understand how the modulation of the microbiota can influence the functioning of other organs, with the main interest being the brain .

Subsequent studies led to the intuition and emergence of the role of the microbiota in the morbidity of various pathologies.

Kolfarma's commitment therefore becomes that of promoting projects to understand how the modulation of the microbiota can influence the functioning of other organs, with a primary interest in the brain.

Furthermore, Kolfarma is strongly committed to the dissemination of new knowledge by actively participating and sponsoring activities such as, among others, conferences and congresses, workshops, webinars, and educational campaigns.

Kolfarma continues to research and deepen the role of the microbiota not only in the control of epileptic seizures but also in the management of various neuropsychiatric disorders, with great attention to the pediatric area.

Kolfarma has funded and continues to fund preclinical and clinical studies , and has been a sponsor of several national and international conferences for years.

Kolfarma owns 7 granted national and international patents, and 9 patents awaiting grant , proving the quality and seriousness of the research carried out and products marketed internationally.